KEFAN LIU¹, XIAOSONG WANG¹, XIN YANG¹, BOWEN SHI¹, LEI XING^2,*, JUNXIA CHEN^1,*

Oncology Research, Vol.33, No.7, pp. 1709-1722, 2025, DOI:10.32604/or.2025.061721 - 26 June 2025

Abstract Background: Accumulating studies have shown the important role of circular RNAs (circRNAs) in the oncogenesis and metastasis of various cancers. We previously reported that circACTN4 could bind with FUBP1 to promote tumorigenesis and the development of breast cancer (BC) by increasing the expression of MYC. However, its exact molecular mechanism and biological function have not been fully elucidated. Methods: Here, Circular RNA microarray analysis was conducted in 3 pairs of BC and paracancerous tissues. The expression of circACTN4 in BC cells and tissues was detected via reverse transcription‒quantitative PCR (RT‒qPCR). Cell Counting Kit-8 (CCK-8), 5-ethynyl-2-deoxyuridine… More > Graphic Abstract

Gege Liu^#, Houfang Zhang^#, Yunhui Peng^*

BIOCELL, Vol.49, No.4, pp. 519-538, 2025, DOI:10.32604/biocell.2025.061470 - 30 April 2025

Abstract Nucleosomes play a vital role in chromatin organization and gene regulation, acting as key hubs that interact with various chromatin-associated factors through diverse binding mechanisms. Recent research has highlighted the prevalence of mutations in linker histones across different types of cancer, emphasizing their critical involvement in cancer progression. These cancer-associated mutations in linker histones have been shown to disrupt nucleosome stacking and the formation of higher-order chromatin structures, which in turn significantly affect epigenetic regulatory processes. In this review, we provide a comprehensive analysis of how cancer-associated linker histone mutations alter their physicochemical properties, influencing More >

XIAOBI HUANG¹, CHUNYUAN CHEN², YONGYANG CHEN¹, HONGLIAN ZHOU¹, YONGHUA CHEN¹, ZHONG HUANG¹, YULIU XIE¹, BAIYANG LIU¹, YUDONG GUO¹, ZHIXIONG YANG¹, GUANGHUA CHEN³, WENMEI SU^1,4

Oncology Research, Vol.33, No.5, pp. 1249-1250, 2025, DOI:10.32604/or.2024.061822 - 18 April 2025

Abstract This article has no abstract. More >

AMJAD YOUSUF¹, NAJEEB ULLAH KHAN^2,*

Oncology Research, Vol.33, No.4, pp. 851-861, 2025, DOI:10.32604/or.2025.058956 - 19 March 2025

Abstract Breast cancer is a significant global concern, with limited effective treatment options. Therefore, therapies with high efficacy and low complications, unlike the existing chemotherapies, are urgently required. To address this issue, advances have been made in therapies targeting molecular pathways related to the murine double minute 2 proto-oncogene (MDM2)-tumor proteinp53 (TP53) interaction. This review aims to investigate the efficacy of MDM2 inhibition in restoring TP53 activity in breast cancer cells, as evidenced by clinical studies, reviews, and trials. TP53 is a tumor suppressor and MDM2 facilitates proteasomal degradation of TP53. MDM2 and TP53 activity More > Graphic Abstract

GUANGXIAN YOU¹, QIAO YANG², XIN LI², LILI CHEN^2,*

Oncology Research, Vol.33, No.4, pp. 905-917, 2025, DOI:10.32604/or.2024.052089 - 19 March 2025

Abstract Background: Lung cancer remains a major factor causing cancer-associated mortality globally. While there have been advancements in treatment options, advanced lung cancer patients still have poor outcomes. This study aims to investigate the potential role of Transmembrane protein 33 (TMEM33) in the development of lung adenocarcinoma. Methods: We leveraged The Cancer Genome Atlas (TCGA) database to analyze the connection between TMEM33 expression to the prognosis of lung adenocarcinoma (LUAD). Cell proliferation, invasiveness, and sphere formation were analyzed by various experiments. The association of miR-214-3p with TMEM33 was explored using luciferase reporter assay, immunoblotting, and real-time… More >

Oncology Research Editorial Office

Oncology Research, Vol.33, No.3, pp. 735-735, 2025, DOI:10.32604/or.2024.056907 - 28 February 2025

Abstract This article has no abstract. More >

BAOXING HUANG^1,#, ZICHANG JIA^1,#, CHENCHEN FU², MOXIAN CHEN², ZEZHUO SU^3,*, YUNSHENG CHEN^1,*

Oncology Research, Vol.33, No.3, pp. 567-575, 2025, DOI:10.32604/or.2024.051672 - 28 February 2025

Abstract Lipocalin-2 (LCN2) is a member of the lipocalin superfamily with multiple functions and can participate in the transport of a variety of small lipophilic ligands in vivo. LCN2 is significantly expressed in various tumors and plays an important role in regulating tumor cell proliferation, invasion, and metastasis. The specific actions of LCN2 in tumors may vary depending on the particular type of cancer involved. In this review, we provide an extensive overview of the transcriptional and post-transcriptional regulation of LCN2 in health and disease. Furthermore, we summarize the impact of LCN2 dysregulation in a broad range More >

HYEON JU LEE¹, CHANG SEOP LEE¹, SI HOON KIM¹, SOOKYUNG KIM¹, JEONG MI KIM¹, SUN-WHA IM¹, YU-JIN JUNG², SEUNG-PYO HONG³, HYUNJUNG LEE³, JONG-IL KIM^3,4,5, JEONG A. HAN^1,*

BIOCELL, Vol.48, No.10, pp. 1455-1464, 2024, DOI:10.32604/biocell.2024.054538 - 02 October 2024

Abstract Objective: Transformation from normal cells to malignant cells is the basis for tumorigenesis. While this cell transformation is known to result from aberrant activation or inactivation of associated genes, these genes have not yet been fully identified. In addition, DNAJs, proteins with a J domain, are known to be molecular co-chaperones, but their cellular functions remain largely unexplored. In this context, we here identified DNAJA4, DNAJB11, and DNAJC10 as pro-transforming genes and elucidated their action mechanisms. Methods: Senescence-associated (SA)-β-galactosidase staining and western blotting were used to analyze cellular senescence and protein expression. Soft agar assay was used… More >

CHUN-HUA WANG^1,2, LU-KAI WANG³, RONG-YAUN SHYU⁴, FU-MING TSAI^5,*

BIOCELL, Vol.48, No.9, pp. 1285-1297, 2024, DOI:10.32604/biocell.2024.053746 - 04 September 2024

Abstract Tazarotene-induced gene 1 (TIG1) is induced by a derivative of vitamin A and is known to regulate many important biological processes and control the development of cancer. TIG1 is widely expressed in various tissues; yet in many cancer tissues, it is not expressed because of the methylation of its promoter. Additionally, the expression of TIG1 in cancer cells inhibits their growth and invasion, suggesting that TIG1 acts as a tumor suppressor gene. However, in some cancers, poor prognosis is associated with TIG1 expression, indicating its protumor growth characteristics, especially in promoting the invasion of inflammatory breast cancer More >

XIAOBI HUANG^1,#, CHUNYUAN CHEN², YONGYANG CHEN^1,#, HONGLIAN ZHOU¹, YONGHUA CHEN¹, ZHONG HUANG¹, YULIU XIE¹, BAIYANG LIU¹, YUDONG GUO¹, ZHIXIONG YANG¹, GUANGHUA CHEN^3,*, WENMEI SU^1,4,*

Oncology Research, Vol.32, No.7, pp. 1185-1195, 2024, DOI:10.32604/or.2023.030771 - 20 June 2024

Abstract Background: Long non-coding RNAs are important regulators in cancer biology and function either as tumor suppressors or as oncogenes. Their dysregulation has been closely associated with tumorigenesis. LINC00265 is upregulated in lung adenocarcinoma and is a prognostic biomarker of this cancer. However, the mechanism underlying its function in cancer progression remains poorly understood. Methods: Here, the regulatory role of LINC00265 in lung adenocarcinoma was examined using lung cancer cell lines, clinical samples, and xenografts. Results: We found that high levels of LINC00265 expression were associated with shorter overall survival rate of patients, whereas knockdown of LINC00265 inhibited proliferation… More >